Cargando…

PSMA PET in Imaging Prostate Cancer

After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsechelidis, Ioannis, Vrachimis, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832487/
https://www.ncbi.nlm.nih.gov/pubmed/35155262
http://dx.doi.org/10.3389/fonc.2022.831429
_version_ 1784648730542080000
author Tsechelidis, Ioannis
Vrachimis, Alexis
author_facet Tsechelidis, Ioannis
Vrachimis, Alexis
author_sort Tsechelidis, Ioannis
collection PubMed
description After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics combining radiological and nuclear medicine scans like CT, MRI and bone scintigraphy (BS). The most recent nuclear medicine development is the prostate specific membrane antigen (PSMA) PET and is emerging as the most promising tool of medical imaging, gaining ground every day. Nevertheless, the different onset among multiple studies fails to establish a worldwide admission and incorporation of this technique in guidelines and its position in workaday medical algorithms. It seems that the medical community agrees not to utilize PSMA PET for low-risk patients; intense debate and research is ongoing for its utility in intermediate risk patients. Contrariwise, in high-risk patients PSMA PET is confirmed outperforming CT and BS combined. Additionally, irrespectively to their castration status, patients with biochemical failure should be referred for PSMA PET. Even though PSMA PET reveals more extended disease than expected or exonerates equivalent lesions, thus impacting treatment optimization. Studies being in progress and future trials with clarify whether PSMA PET will be the new gold standard technic for specific groups of patients.
format Online
Article
Text
id pubmed-8832487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88324872022-02-12 PSMA PET in Imaging Prostate Cancer Tsechelidis, Ioannis Vrachimis, Alexis Front Oncol Oncology After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on “classic” imaging technics combining radiological and nuclear medicine scans like CT, MRI and bone scintigraphy (BS). The most recent nuclear medicine development is the prostate specific membrane antigen (PSMA) PET and is emerging as the most promising tool of medical imaging, gaining ground every day. Nevertheless, the different onset among multiple studies fails to establish a worldwide admission and incorporation of this technique in guidelines and its position in workaday medical algorithms. It seems that the medical community agrees not to utilize PSMA PET for low-risk patients; intense debate and research is ongoing for its utility in intermediate risk patients. Contrariwise, in high-risk patients PSMA PET is confirmed outperforming CT and BS combined. Additionally, irrespectively to their castration status, patients with biochemical failure should be referred for PSMA PET. Even though PSMA PET reveals more extended disease than expected or exonerates equivalent lesions, thus impacting treatment optimization. Studies being in progress and future trials with clarify whether PSMA PET will be the new gold standard technic for specific groups of patients. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8832487/ /pubmed/35155262 http://dx.doi.org/10.3389/fonc.2022.831429 Text en Copyright © 2022 Tsechelidis and Vrachimis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tsechelidis, Ioannis
Vrachimis, Alexis
PSMA PET in Imaging Prostate Cancer
title PSMA PET in Imaging Prostate Cancer
title_full PSMA PET in Imaging Prostate Cancer
title_fullStr PSMA PET in Imaging Prostate Cancer
title_full_unstemmed PSMA PET in Imaging Prostate Cancer
title_short PSMA PET in Imaging Prostate Cancer
title_sort psma pet in imaging prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832487/
https://www.ncbi.nlm.nih.gov/pubmed/35155262
http://dx.doi.org/10.3389/fonc.2022.831429
work_keys_str_mv AT tsechelidisioannis psmapetinimagingprostatecancer
AT vrachimisalexis psmapetinimagingprostatecancer